AvengeBio was a biotechnology company that is now permanently closed.

AvengeBio

IPhone / Mobile Compatible

Viewport Meta

SSL by Default

nginx

DMARC

DNSSEC

Microsoft Exchange Online

Office 365 Mail

Microsoft Azure DNS

Owner, Ny Network Solutions

John Handley

Co-Founder

Paul Wotton

Senior Director Product Development

Guillaume Carmona

Sr. Director of Process Development

Lauren Jansen

Senior Director, External Manufacturing and Supply Chain

Zeke Johnston

Executive Assistant & Office Manager

Angela Lam

Quality Assurance Manager

Kaylyn Harris

Project Management

Aadhar Mahajan

VP, Corporate Development

Ryan Newman

Josh Richardson

Ben Askew

Michael T. Heffernan

Scott Morenstein

Claudio Dansky Ullmann

Chief Medical Officer

Omid Veiseh

founder

Co-Founder and Director

Founder & CEO

Medical Companies With Less Than $10M in Revenue (Top 10K)

Northeastern US Companies With Less Than $1B in Revenue (Top 10K)

Northeastern US Early Stage Companies With More Than $1M in Revenue

Perceptive Advisors Portfolio Companies

AvengeBio is focusing on Cell-Generated Immunotherapies to eradicate solid tumors. It is a developer of a drug delivery platform intended to treat cancer. The company was founded in 2019 and based in Cambridge, Massachusetts.

CAM Capital

Perceptive Advisors

Series A - AvengeBio

Seed Round - AvengeBio

Cambridge

Massachusetts

United States

North America

Avenge Bio, a cell therapy biotech from Rice, is closed

Avenge Bio to Participate in Upcoming Investor Conference

Avenge Bio Appoints Claudio Dansky Ullmann, M.D., as Chief Medical Officer

Avenge Bio Locks Up $45M in Series A

Avenge Bio Announces Peer-Reviewed Publication on Preclinical Proof of Concept for LOCOcyte™ Platform Technology

Avenge Bio Appoints Douglas Carlson as Chief Operating and Financial Officer

Avenge Bio Raises $45 Million In Series A Funding

Startup Avenge Bio nabs $45M for novel cell therapy approach to ovarian cancer

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Oct 15, 2024 3:10 PM	160ac86f
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Oct 15, 2024 3:10 PM	054691e8
crunchbase trigger	general	Oct 30, 2024 1:02 PM	20d324b1
crunchbase profile	general	Oct 30, 2024 6:17 PM	2c7ab6f6
li profile	general
translate crunchbase fundingrounds	general	Nov 6, 2024 3:12 PM	9933c765
peers	general	Oct 15, 2024 3:10 PM	3cde6770
news basic	general	Oct 15, 2024 3:10 PM	106ba0ef
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

AVEN

COM:AVENGEBIO

AvengeBio